Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹923.80down ₹22.20 (2.35%)BSE ₹924.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹946.00.
30 Oct: open ₹946.00, high ₹951.80, low ₹920.00
52-week range of traded prices to 30 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Next results date: the board meets on 13 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,714 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 41.79
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 35.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.54%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,22937.1% delivered
Jubilant Pharmova share news and announcements
1,152 announcements, routine notices left out, newest first. Page 21 of 24.
Feb 2010
23 Feb · Meeting
Proceedings of the Extraordinary General Meeting of the members of the company held on February 20, 2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Feb · Updates
Vide its letter dated February 22, 2010, a copy of the Presentation which the Company proposes to make to Investors / Analysts. The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Feb · Exercise of Stock Options
At a meeting of the Compensation Committee of the Board of Directors held today i.e. February 20, 2010, pursuant to exercise of 57,054 options, the Committee has approved transfer by Jubilant Employees Welfare Trust to the option holders, of 285,270 equity shares of Re.1 each at an exercise price of Rs. 201.33 each
Jan 2010
27 Jan · Meeting
Notice of the Extra-Ordinary General Meeting of the Members of the company to be held on February 20, 2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Board meeting
At a meeting of the Board of Directors of the Company held on January 21, 2010, inter alia, the following decisions have been taken: 1) The Board has accorded approval for raising additional capital through issue of Equity / GDRs / ADRs / FCCBs or others equity related instruments or issue of equity or equity related instruments to Qualified Institutional Buyers (QIBs) of Rs.1000 Crores subjects to approval of members and other necessary approvals. 2) Dr Inder Mohan Verma has been appointed as additional Directors of the Company. He will be an independent director. 3) In line with the continued strategy of enhancing our focus as a Pharma and life Science Company, the Board has in principal approved the Demerger of its Agri and Performance Polymer business into a separate Company for pursuing the growth prospects of both the business independently and efficiently. The detailed Demerger Scheme is expected to be approved in the meeting to be held in the first quarter of FY 2010-11.21 Jan · Exercise of Stock Options
At a meeting of the Compensation Committee of the Board of Directors held today i.e. January 21, 2010, pursuant to exercise of 89,627 options, the Committee has approved transfer by Jubilant Employees Welfare Trust to the option holders, of 448,135 equity shares of Re.1 each at an exercise price of Rs. 201.33 each21 Jan · Business
Press release dated January 21, 2010, titled "Revenue up by 6% to Rs.961 crore; EBITDA up52% to Rs.238 crore; PAT up 215% at Rs. 101 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 61249 lacs for quarter ending on 31-DEC-2009 against Rs. 58741 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 7057 lacs for the quarter ending on 31-DEC-2009 against Rs. (2116) lacs for the quarter ending on 31-DEC-2008.21 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 96148 lacs for quarter ending on 31-DEC-2009 against Rs. 90964 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 10080 lacs for the quarter ending on 31-DEC-2009 against Rs. (8757) lacs for the quarter ending on 31-DEC-2008.13 Jan · Board meeting
Meeting on 21 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009/Unaudited Financial Results/Others”
Dec 2009
2 Dec · Results
Based on the Postal Ballot forms received from shareholders and as per the Scrutinizer's Report dated December 02, 2009, the resolutions have been declared passed with requisite majority, through postal ballot. The details of the Results of the postal ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Dec · Business
Press release dated December 01, 2009, titled "Jubilant and Lilly Extend Drug Discovery Collaboration on Sucessful Delivery of Pre-clinical Candidates". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2009
24 Nov · Business
Press release dated November 23, 2009, titled "Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Nov · Business
Press release dated November 10, 2009, titled "Duke University & Jubilant Organosys Announce Intent to Enter Global Research and Drug Development Partnership". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Nov · Disclosure
Disclosures of pledge of shares under Regulation 8A(4) of SEBI (SAST) Regulations, 1997. The promoters and promoter group hold 50.82% of the Company's capital, out of which 9.65% is pledged. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Nov · Meeting
As per Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001. The following resolutions to be passed through Postal Ballot (1) Authorizing the Board for disposal of Application Polymers Division and Consumer Products Division. (2) Further Issue of Capital. (3) Change of name of the company. A copy of the notice of postal ballot shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Nov · Retirement
Mr. S.N.Singh, Executive Director of the Company, has retired from the services of the Company on November 03, 2009. He ceases to be a Director of the Company also.
Oct 2009
28 Oct · Disclosure
Disclosures of pledge of shares under Regulation 8A(4) of SEBI (SAST) Regulations, 1997. The promoters and promoter group hold 50.82% of the Company's capital, out of which 10.64% is pledged. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Oct · Updates
Performance Highlights Q2 FY 2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Oct · Disclosure
Disclosures dated October 19, 2009, the promoters and promoter group hold 50.82% of the Company's capital, out of which 10.89% is pledged. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Oct · Raising of Capital/Name Change/Others
At a meeting of the Board of Directors of the Company held today, i.e. October 22, 2009 inter-alia, the following decisions have been taken, subject to approval of members and other approvals wherever necessary: (1) Hiving off Application Polymers division and Consumer Products division. (2) Raising capital through issue of equity or equity related instruments upto Rs. 500 Crores. (3) Changing the name of the Company from Jubilant Organosys Limited to Jubilant Life Sciences Limited.22 Oct · Results
Standalone Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 123330 lacs for half year ending on 30-SEP-2009 against Rs. 129525 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 20052 lacs for the half year ending on 30-SEP-2009 against Rs. (988) lacs for the half year ending on 30-SEP-2008.22 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 62736 lacs for quarter ending on 30-SEP-2009 against Rs. 67900 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 5549 lacs for the quarter ending on 30-SEP-2009 against Rs. (2439) lacs for the quarter ending on 30-SEP-2008.22 Oct · Grant of Stock Options
At a Meeting of the Compensation Committee of the Board of Directors held today i.e. October 22, 2009, 41523 Options have been granted to eligible employees of the Company, in accordance with Jubilant Employees Stock Option Plan, 2005. Each option shall entitle the holder to subscribe to 5 equity shares of Re. 1 each at a price of Rs. 221.60 per share. Further, pursuant to exercise of 600 options, the Committee has approved transfer by Jubilant Employees Welfare Trust to the Option holder, of 3000 equity shares of Re. 1 each at an exercise price of Rs. 201.33 each. The Schedule VI as required under the SEBI ESOP/ESPS Guidelines is not applicable as the shares are already listed.22 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 93311 lacs for quarter ending on 30-SEP-2009 against Rs. 94050 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 5768 lacs for the quarter ending on 30-SEP-2009 against Rs. (6272) lacs for the quarter ending on 30-SEP-2008.22 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 182947 lacs for half year ending on 30-SEP-2009 against Rs. 176710 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 18350 lacs for the half year ending on 30-SEP-2009 against Rs. (4996) lacs for the half year ending on 30-SEP-2008.22 Oct · Business
Press release dated October 22, 2009, titled "Revenue for Q2 FY 2010 at Rs.933 crore, EBITDA for the quarter at Rs.192 crore with EBITDA margins of 20.5% and Net Profit at Rs.58 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Oct · Board meeting
Meeting on 22 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009/Unaudited Financial Results/Others”
Sep 2009
2 Sep · Meeting
Proceedings of the Annual General Meeting of the Company held on August 28, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2009
28 Aug · Updates
Chairman's Speech delivered at the Annual General Meeting of the Company held on August 28, 2009.A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Aug · Meeting
Notice of the Annual General Meeting of the Members of the Company to be held on August 28, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
14 Jul · Business
Press release dated July 14, 2009, titled "Q1 FY10 Revenues up 8% to Rs.896 crore; Q1 FY 10 PAT at Rs.126 crore ". Further the Company has also submitted a copy of Performance Highlights Q1 FY 2010. A copy of the press release and Performance Highlights shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 60594 lacs for quarter ending on 30-JUN-2009 against Rs. 61625 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 14503 lacs for the quarter ending on 30-JUN-2009 against Rs. 1451 lacs for the quarter ending on 30-JUN-2008.14 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 89636 lacs for quarter ending on 30-JUN-2009 against Rs. 82660 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 12582 lacs for the quarter ending on 30-JUN-2009 against Rs. 1276 lacs for the quarter ending on 30-JUN-2008.6 Jul · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2009.2 Jul · Updates
Company Statement on Product Recall, being issued on July 02, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
17 Jun · Corporate action
Register of Members and Share Transfer Books of the Company will remain closed from July 01, 2009 to July 11, 2009, both days inclusive, to determine entitlement of dividend. The Board has recommended dividend of Rs.1.50 per equity share (of Re. 1 each) for the year ended March 31, 2009.16 Jun · Updates
Vide its letter dated June 15, 2009 that the Company is organising an Analysts' Conference on June 15,2009. A copy of the presentation shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Jun · News Verification
News Verification : The media had reports that Jubilant Organosys Limited may hive off a part of its Industrial and Performance Products (IPP) division. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Jubilant Organosys Limited has vide its letter inter-alia stated, " The company is strategically focussing on Pharmaceuticals & Life sciences Products and Services business and has identified Performance Polymers business as a non core business.Accordingly, the company is preliminarily evaluating for divestment of Performance Polymers business being non core to Jubilant. At an appropriate time and price the company will take a decision on such divestment."11 Jun · Business
Press release dated June 11, 2009, titled "Jubilant to Work with Endo Pharmaceuticals on Drug development,Collaboration to provide Endo Pharmaceuticals with new drug candidates in Oncology ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
20 May · Foreign Currency Convertible Bonds
FCCB'S of US$ 35 million issued in 2004 fell due for redemption on May 15, 2009.The outstanding amount of these bonds viz.US$ 3,00,000 was paid to the bondholders. All these FCCBs have now been cancelled.5 May · Business
Press release dated May 05, 2009, titled "Jubilant Enters Research Collaboration with AstraZeneca". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 May · Business
Press release dated May 04, 2009, titled "DRAXIMAGE(R)'s generic Sestamibi Approved for launch in USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
28 Apr · Updates
Particulars under Clause 20 of the Listing Agreement, for the year ended March 31, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Apr · Results
Consolidated Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 351798 lacs for year ending on 31-MAR-2009 against Rs. 248890 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 28318 lacs for the year ending on 31-MAR-2009 against Rs. 40050 lacs for the year ending on 31-MAR-2008.28 Apr · Results
Standalone Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 243072 lacs for year ending on 31-MAR-2009 against Rs. 197670 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 26074 lacs for the year ending on 31-MAR-2009 against Rs. 39230 lacs for the year ending on 31-MAR-2008.28 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 54806 lacs for quarter ending on 31-MAR-2009 against Rs. 53430 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. (1529) lacs for the quarter ending on 31-MAR-2009 against Rs. 5710 lacs for the quarter ending on 31-MAR-2008.28 Apr · Business
Press release dated April 28, 2009, titled "FY09 Revenues up 41% to Rs.3,518 crore; FY09 operating EBIDTA (excluding Forex impact) up 51% to Rs.716 crs". Further the Company has also submitted a copy of Performance Highlights Q4 and FY 2009. A copy of the press release and Performance Highlights shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 84124 lacs for quarter ending on 31-MAR-2009 against Rs. 68900 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 1237 lacs for the quarter ending on 31-MAR-2009 against Rs. 5820 lacs for the quarter ending on 31-MAR-2008.28 Apr · Dividend
Board of Directors at their meeting held on April 28, 2009 has recommended a dividend of Rs. 1.50 per equity share of Re. 1 totaling to Rs. 2589.25 lacs, subject to approval in Annual General Meeting.